AU2020240035A1 - Tumor-selective combination therapy - Google Patents

Tumor-selective combination therapy Download PDF

Info

Publication number
AU2020240035A1
AU2020240035A1 AU2020240035A AU2020240035A AU2020240035A1 AU 2020240035 A1 AU2020240035 A1 AU 2020240035A1 AU 2020240035 A AU2020240035 A AU 2020240035A AU 2020240035 A AU2020240035 A AU 2020240035A AU 2020240035 A1 AU2020240035 A1 AU 2020240035A1
Authority
AU
Australia
Prior art keywords
tumor
nqol
cells
lap
dnq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020240035A
Other languages
English (en)
Inventor
David Boothman
Yang-Xin Fu
Paul J. Hergenrother
Xiumei HUANG
Lingxiang JIANG
Xiaoguang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
University of Texas System
University of Illinois System
Original Assignee
Indiana University Research and Technology Corp
University of Texas System
University of Illinois at Urbana Champaign
University of Texas at Austin
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp, University of Texas System, University of Illinois at Urbana Champaign, University of Texas at Austin, University of Illinois System filed Critical Indiana University Research and Technology Corp
Publication of AU2020240035A1 publication Critical patent/AU2020240035A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020240035A 2019-03-18 2020-03-18 Tumor-selective combination therapy Abandoned AU2020240035A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819870P 2019-03-18 2019-03-18
US62/819,870 2019-03-18
PCT/US2020/023250 WO2020190990A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Publications (1)

Publication Number Publication Date
AU2020240035A1 true AU2020240035A1 (en) 2021-10-07

Family

ID=72519160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020240035A Abandoned AU2020240035A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Country Status (10)

Country Link
US (1) US20220160703A1 (enExample)
EP (1) EP3942061A4 (enExample)
JP (1) JP2022525476A (enExample)
KR (1) KR20220004025A (enExample)
CN (1) CN113905763A (enExample)
AU (1) AU2020240035A1 (enExample)
BR (1) BR112021018545A2 (enExample)
CA (1) CA3130513A1 (enExample)
MX (1) MX2021011301A (enExample)
WO (1) WO2020190990A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2619331T3 (enExample) * 2010-09-22 2018-07-28
ES2853973T3 (es) * 2013-04-09 2021-09-20 The Board Of Trustees Of The Univ Of Illionis Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
KR20230020549A (ko) * 2016-03-24 2023-02-10 코테라 바이오사이언스 인코포레이티드 Tg02를 사용한 암의 치료
AU2018304458B2 (en) * 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer

Also Published As

Publication number Publication date
US20220160703A1 (en) 2022-05-26
EP3942061A1 (en) 2022-01-26
BR112021018545A2 (pt) 2021-12-14
KR20220004025A (ko) 2022-01-11
CA3130513A1 (en) 2020-09-24
MX2021011301A (es) 2022-01-19
CN113905763A (zh) 2022-01-07
JP2022525476A (ja) 2022-05-16
WO2020190990A1 (en) 2020-09-24
EP3942061A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
ES2622527T3 (es) Inhibidores de CSF-1R para el tratamiento de tumores de cerebro
JP6426706B2 (ja) がん処置で使用するためのｇｌａ単剤療法
JP6719620B2 (ja) 腫瘍選択的併用療法
Zhang et al. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies
CN101888777A (zh) 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
CA3144985A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
US11224608B2 (en) Compounds and methods for treating cancer
Sai et al. Basic and translational research on carbon-ion radiobiology
AU2020240035A1 (en) Tumor-selective combination therapy
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer
US20250375458A1 (en) Compositions and methods to combat multidrug-resistant and persistent t-cell-mediated, oncological and infectious diseases
US12037327B2 (en) Compounds and methods targeting GPER for treatment of diseases associated with calcium
WO2023069943A1 (en) Combination decitabine and mps1 inhibitor therapy to prime cancer immunogenicity
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
HK1150514A (en) Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application